Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiac Resynchronization Therapy | 39 | 2023 | 68 | 12.470 |
Why?
|
Bundle-Branch Block | 24 | 2024 | 54 | 8.090 |
Why?
|
Bundle of His | 21 | 2024 | 45 | 8.090 |
Why?
|
Electrocardiography | 31 | 2024 | 493 | 5.500 |
Why?
|
Defibrillators, Implantable | 18 | 2024 | 141 | 5.010 |
Why?
|
Heart Failure | 28 | 2023 | 1173 | 4.870 |
Why?
|
Atrial Fibrillation | 17 | 2023 | 348 | 4.730 |
Why?
|
Tachycardia, Ventricular | 16 | 2023 | 121 | 3.390 |
Why?
|
Catheter Ablation | 21 | 2024 | 250 | 2.950 |
Why?
|
Cardiac Pacing, Artificial | 15 | 2024 | 97 | 2.380 |
Why?
|
Electrophysiologic Techniques, Cardiac | 10 | 2024 | 50 | 1.980 |
Why?
|
Heart Conduction System | 14 | 2023 | 112 | 1.890 |
Why?
|
Arrhythmias, Cardiac | 12 | 2023 | 197 | 1.760 |
Why?
|
Heart Rate | 10 | 2023 | 492 | 1.680 |
Why?
|
Heart Ventricles | 14 | 2020 | 779 | 1.540 |
Why?
|
Treatment Outcome | 42 | 2024 | 8170 | 1.320 |
Why?
|
Cardiac Resynchronization Therapy Devices | 7 | 2019 | 19 | 1.290 |
Why?
|
Pacemaker, Artificial | 6 | 2021 | 94 | 1.160 |
Why?
|
Humans | 102 | 2024 | 88786 | 1.090 |
Why?
|
Anti-Arrhythmia Agents | 3 | 2019 | 64 | 0.970 |
Why?
|
Death, Sudden, Cardiac | 4 | 2024 | 51 | 0.920 |
Why?
|
Heart Septum | 3 | 2024 | 47 | 0.910 |
Why?
|
Tachycardia, Atrioventricular Nodal Reentry | 3 | 2020 | 23 | 0.890 |
Why?
|
Cardiomyopathies | 7 | 2020 | 263 | 0.870 |
Why?
|
Aged | 48 | 2024 | 18994 | 0.870 |
Why?
|
Body Surface Potential Mapping | 5 | 2021 | 25 | 0.860 |
Why?
|
Echocardiography | 9 | 2019 | 935 | 0.840 |
Why?
|
Mitral Valve Insufficiency | 4 | 2019 | 192 | 0.830 |
Why?
|
Atrioventricular Block | 4 | 2024 | 24 | 0.790 |
Why?
|
Middle Aged | 39 | 2024 | 25759 | 0.770 |
Why?
|
Heart Atria | 3 | 2020 | 281 | 0.720 |
Why?
|
Female | 55 | 2024 | 45856 | 0.710 |
Why?
|
Anticoagulants | 2 | 2023 | 425 | 0.710 |
Why?
|
Male | 54 | 2024 | 42099 | 0.700 |
Why?
|
Prospective Studies | 19 | 2024 | 4255 | 0.690 |
Why?
|
Purkinje Fibers | 1 | 2019 | 27 | 0.670 |
Why?
|
Cardiac Imaging Techniques | 1 | 2019 | 25 | 0.660 |
Why?
|
Electric Countershock | 2 | 2024 | 53 | 0.650 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2019 | 70 | 0.650 |
Why?
|
Atrioventricular Node | 5 | 2024 | 35 | 0.580 |
Why?
|
Ventricular Function, Right | 1 | 2017 | 146 | 0.550 |
Why?
|
Action Potentials | 2 | 2020 | 595 | 0.540 |
Why?
|
Atrial Flutter | 4 | 2020 | 35 | 0.540 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 602 | 0.540 |
Why?
|
Spinal Cord Stimulation | 1 | 2015 | 15 | 0.530 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 205 | 0.510 |
Why?
|
Hospitalization | 4 | 2018 | 873 | 0.490 |
Why?
|
Cause of Death | 1 | 2015 | 266 | 0.480 |
Why?
|
Retrospective Studies | 22 | 2024 | 8951 | 0.440 |
Why?
|
Streptococcal Infections | 1 | 2012 | 57 | 0.420 |
Why?
|
Myocarditis | 1 | 2012 | 52 | 0.410 |
Why?
|
Equipment Failure | 1 | 2012 | 121 | 0.410 |
Why?
|
Bradycardia | 2 | 2022 | 40 | 0.400 |
Why?
|
Postoperative Complications | 3 | 2021 | 2273 | 0.400 |
Why?
|
Growth Differentiation Factor 10 | 1 | 2011 | 1 | 0.390 |
Why?
|
Antigens, Ly | 1 | 2011 | 37 | 0.380 |
Why?
|
Ventricular Fibrillation | 3 | 2023 | 67 | 0.380 |
Why?
|
Incidence | 6 | 2018 | 1592 | 0.380 |
Why?
|
Follow-Up Studies | 14 | 2021 | 3648 | 0.380 |
Why?
|
Epicardial Mapping | 2 | 2021 | 10 | 0.370 |
Why?
|
Ventricular Dysfunction, Left | 5 | 2014 | 328 | 0.370 |
Why?
|
Sick Sinus Syndrome | 2 | 2021 | 9 | 0.360 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2011 | 125 | 0.360 |
Why?
|
Ventricular Remodeling | 7 | 2020 | 105 | 0.350 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 266 | 0.350 |
Why?
|
Registries | 2 | 2024 | 765 | 0.350 |
Why?
|
Cicatrix | 3 | 2023 | 66 | 0.340 |
Why?
|
Device Removal | 2 | 2021 | 167 | 0.330 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 321 | 0.330 |
Why?
|
Mitral Valve | 3 | 2020 | 261 | 0.310 |
Why?
|
Risk Factors | 11 | 2024 | 5446 | 0.310 |
Why?
|
GTPase-Activating Proteins | 1 | 2008 | 67 | 0.300 |
Why?
|
Wnt Proteins | 1 | 2008 | 130 | 0.300 |
Why?
|
Prosthesis Implantation | 3 | 2021 | 126 | 0.300 |
Why?
|
beta Catenin | 1 | 2008 | 266 | 0.280 |
Why?
|
Digestive System Surgical Procedures | 2 | 2007 | 126 | 0.270 |
Why?
|
Myocardial Ischemia | 4 | 2019 | 161 | 0.270 |
Why?
|
Ventricular Septum | 2 | 2024 | 14 | 0.270 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2020 | 161 | 0.270 |
Why?
|
Cohort Studies | 5 | 2019 | 2850 | 0.270 |
Why?
|
Aged, 80 and over | 10 | 2024 | 6754 | 0.260 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 1711 | 0.260 |
Why?
|
Myocardium | 2 | 2020 | 571 | 0.240 |
Why?
|
Membrane Proteins | 1 | 2011 | 1214 | 0.240 |
Why?
|
Lower Gastrointestinal Tract | 1 | 2004 | 8 | 0.240 |
Why?
|
Patient Selection | 2 | 2022 | 682 | 0.230 |
Why?
|
Esophageal Fistula | 1 | 2023 | 11 | 0.230 |
Why?
|
Electrodes, Implanted | 3 | 2012 | 177 | 0.220 |
Why?
|
Risk Assessment | 6 | 2024 | 2285 | 0.210 |
Why?
|
Heart-Assist Devices | 4 | 2018 | 753 | 0.210 |
Why?
|
Feasibility Studies | 6 | 2021 | 777 | 0.200 |
Why?
|
Stroke Volume | 3 | 2022 | 461 | 0.200 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 430 | 0.200 |
Why?
|
Ventricular Premature Complexes | 1 | 2021 | 8 | 0.200 |
Why?
|
Prognosis | 5 | 2023 | 3753 | 0.200 |
Why?
|
Treatment Failure | 3 | 2017 | 287 | 0.200 |
Why?
|
Recurrence | 6 | 2024 | 1136 | 0.190 |
Why?
|
Crohn Disease | 2 | 2007 | 754 | 0.190 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 10 | 0.190 |
Why?
|
Prosthesis-Related Infections | 1 | 2021 | 60 | 0.190 |
Why?
|
Electrophysiology | 1 | 2021 | 403 | 0.180 |
Why?
|
Pulmonary Veins | 2 | 2012 | 92 | 0.180 |
Why?
|
Global Health | 2 | 2021 | 186 | 0.180 |
Why?
|
Gadolinium | 1 | 2020 | 103 | 0.180 |
Why?
|
Severity of Illness Index | 4 | 2019 | 1835 | 0.180 |
Why?
|
Infection Control | 1 | 2021 | 120 | 0.180 |
Why?
|
Vena Cava, Superior | 1 | 2020 | 60 | 0.180 |
Why?
|
Ultrasonography, Interventional | 1 | 2020 | 123 | 0.170 |
Why?
|
Cardiac Catheters | 1 | 2019 | 12 | 0.170 |
Why?
|
Time Factors | 4 | 2024 | 5309 | 0.170 |
Why?
|
Cardiac Catheterization | 2 | 2018 | 301 | 0.160 |
Why?
|
Single-Blind Method | 1 | 2019 | 150 | 0.160 |
Why?
|
Medicare | 2 | 2024 | 422 | 0.160 |
Why?
|
United States | 6 | 2024 | 6926 | 0.160 |
Why?
|
Tachycardia | 1 | 2018 | 37 | 0.160 |
Why?
|
Computer Security | 1 | 2018 | 16 | 0.160 |
Why?
|
Inferior Wall Myocardial Infarction | 1 | 2018 | 2 | 0.160 |
Why?
|
Artificial Intelligence | 1 | 2021 | 319 | 0.150 |
Why?
|
Myocardial Contraction | 1 | 2019 | 252 | 0.150 |
Why?
|
Intensive Care Units | 1 | 2021 | 394 | 0.150 |
Why?
|
Thromboembolism | 1 | 2018 | 120 | 0.140 |
Why?
|
Forecasting | 2 | 2015 | 305 | 0.140 |
Why?
|
Cardiology | 1 | 2017 | 114 | 0.140 |
Why?
|
Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.130 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 781 | 0.130 |
Why?
|
Coronary Angiography | 2 | 2014 | 239 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2017 | 1212 | 0.120 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2014 | 33 | 0.120 |
Why?
|
Societies, Medical | 1 | 2017 | 565 | 0.120 |
Why?
|
Quality Improvement | 1 | 2017 | 446 | 0.110 |
Why?
|
Cardiac Conduction System Disease | 2 | 2023 | 7 | 0.110 |
Why?
|
Heart Valve Diseases | 1 | 2014 | 115 | 0.110 |
Why?
|
Walking | 1 | 2014 | 89 | 0.110 |
Why?
|
Pharyngitis | 1 | 2012 | 16 | 0.110 |
Why?
|
Streptococcus pyogenes | 1 | 2012 | 35 | 0.110 |
Why?
|
Creatine Kinase | 1 | 2012 | 52 | 0.110 |
Why?
|
Animals | 4 | 2022 | 27260 | 0.110 |
Why?
|
Heart Failure, Systolic | 1 | 2012 | 5 | 0.110 |
Why?
|
Chest Pain | 1 | 2012 | 43 | 0.100 |
Why?
|
Troponin T | 1 | 2012 | 39 | 0.100 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2014 | 178 | 0.100 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 219 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 188 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2017 | 1233 | 0.100 |
Why?
|
Motor Activity | 1 | 2014 | 327 | 0.100 |
Why?
|
Tachycardia, Paroxysmal | 1 | 2011 | 2 | 0.100 |
Why?
|
Smad3 Protein | 1 | 2011 | 23 | 0.100 |
Why?
|
Equipment Design | 1 | 2012 | 415 | 0.100 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2011 | 45 | 0.100 |
Why?
|
RNA, Neoplasm | 1 | 2011 | 88 | 0.100 |
Why?
|
Renal Dialysis | 1 | 2013 | 335 | 0.090 |
Why?
|
Adult | 7 | 2021 | 26414 | 0.090 |
Why?
|
Green Fluorescent Proteins | 1 | 2011 | 309 | 0.090 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 351 | 0.090 |
Why?
|
Surgery, Computer-Assisted | 1 | 2011 | 98 | 0.090 |
Why?
|
Patient Care Team | 1 | 2012 | 284 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2012 | 372 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2013 | 413 | 0.080 |
Why?
|
Biomarkers | 2 | 2012 | 1751 | 0.080 |
Why?
|
Signal Transduction | 2 | 2011 | 3370 | 0.080 |
Why?
|
Axin Protein | 1 | 2008 | 4 | 0.080 |
Why?
|
Young Adult | 3 | 2021 | 6264 | 0.080 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2008 | 44 | 0.080 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2008 | 48 | 0.080 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2008 | 69 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 1590 | 0.080 |
Why?
|
Cytosol | 1 | 2008 | 192 | 0.080 |
Why?
|
Age Factors | 1 | 2012 | 1861 | 0.080 |
Why?
|
Contrast Media | 2 | 2024 | 1090 | 0.070 |
Why?
|
Mice, Transgenic | 1 | 2011 | 1573 | 0.070 |
Why?
|
Behavior | 1 | 2007 | 85 | 0.070 |
Why?
|
Base Sequence | 1 | 2011 | 2326 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2019 | 2750 | 0.070 |
Why?
|
Interprofessional Relations | 1 | 2007 | 122 | 0.070 |
Why?
|
Perception | 1 | 2007 | 178 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2014 | 858 | 0.070 |
Why?
|
Mice, Knockout | 1 | 2011 | 1989 | 0.070 |
Why?
|
Clinical Clerkship | 1 | 2007 | 118 | 0.070 |
Why?
|
Mice | 2 | 2011 | 11718 | 0.070 |
Why?
|
Zebrafish | 1 | 2008 | 316 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1264 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2011 | 2011 | 0.060 |
Why?
|
Comorbidity | 2 | 2021 | 948 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2008 | 422 | 0.060 |
Why?
|
Ethics, Medical | 1 | 2007 | 307 | 0.060 |
Why?
|
Vagus Nerve Stimulation | 1 | 2024 | 10 | 0.060 |
Why?
|
Heart Injuries | 1 | 2024 | 19 | 0.060 |
Why?
|
Prevalence | 2 | 2018 | 1238 | 0.060 |
Why?
|
Syncope | 1 | 2024 | 34 | 0.060 |
Why?
|
Fluoroscopy | 1 | 2024 | 122 | 0.060 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 3201 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 2012 | 0.060 |
Why?
|
Models, Biological | 1 | 2011 | 1763 | 0.060 |
Why?
|
Atropine | 1 | 2023 | 60 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2024 | 158 | 0.060 |
Why?
|
Heart Block | 1 | 2023 | 31 | 0.060 |
Why?
|
Cell Line | 1 | 2008 | 2494 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 1174 | 0.060 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 217 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2021 | 1849 | 0.050 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 2607 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2023 | 170 | 0.050 |
Why?
|
Students, Medical | 1 | 2007 | 418 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2012 | 226 | 0.050 |
Why?
|
Mortality | 1 | 2021 | 149 | 0.050 |
Why?
|
Survival Rate | 2 | 2015 | 1880 | 0.040 |
Why?
|
Endocardium | 1 | 2020 | 98 | 0.040 |
Why?
|
Vascular System Injuries | 1 | 2020 | 29 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2014 | 360 | 0.040 |
Why?
|
Hemodynamics | 1 | 2023 | 727 | 0.040 |
Why?
|
Prosthesis Design | 1 | 2020 | 295 | 0.040 |
Why?
|
Disease Progression | 2 | 2014 | 1482 | 0.040 |
Why?
|
Survival Analysis | 2 | 2012 | 1534 | 0.040 |
Why?
|
Pericardium | 1 | 2019 | 70 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 1708 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2017 | 112 | 0.040 |
Why?
|
Thoracic Surgical Procedures | 1 | 2017 | 55 | 0.040 |
Why?
|
Heart | 1 | 2020 | 573 | 0.030 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2017 | 202 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 595 | 0.030 |
Why?
|
Cardio-Renal Syndrome | 1 | 2015 | 6 | 0.030 |
Why?
|
Boston | 1 | 2015 | 36 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2014 | 61 | 0.030 |
Why?
|
Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
Capillaries | 1 | 2014 | 90 | 0.030 |
Why?
|
Massachusetts | 1 | 2013 | 31 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2014 | 47 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 94 | 0.030 |
Why?
|
Cardiac Output | 1 | 2012 | 156 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2015 | 1066 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 306 | 0.020 |
Why?
|
Child | 1 | 2023 | 7112 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 848 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2011 | 22 | 0.020 |
Why?
|
Echocardiography, Doppler | 1 | 2012 | 186 | 0.020 |
Why?
|
Adolescent | 1 | 2004 | 9197 | 0.020 |
Why?
|
Risk | 1 | 2012 | 657 | 0.020 |
Why?
|
Pilot Projects | 1 | 2012 | 865 | 0.020 |
Why?
|
Chronic Disease | 1 | 2013 | 946 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 986 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 831 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2014 | 716 | 0.020 |
Why?
|
Observation | 1 | 2007 | 38 | 0.020 |
Why?
|
Italy | 1 | 2007 | 107 | 0.020 |
Why?
|
Japan | 1 | 2007 | 303 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 1146 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2007 | 901 | 0.020 |
Why?
|
Reoperation | 1 | 2007 | 598 | 0.010 |
Why?
|
Quality of Life | 1 | 2012 | 1658 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2007 | 642 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2007 | 625 | 0.010 |
Why?
|